Indication
Stage II Breast Cancer
30 clinical trials
36 products
17 drugs
Clinical trial
A Pilot Single Arm Open Label Trial Evaluating M7824 (Anti-PD-L1/TGF-Beta TRAP) in a Window Setting in Patients With Stage II-III HER2/Neu Positive (HER2+) Breast Cancer (BC)Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
Bintrafusp AlfaClinical trial
Phase II Trial of Rifaximin in Patients With Early Stage HER2 Positive Breast Cancer With Gastrointestinal Toxicities Related to Pertuzumab-Based TherapyStatus: Active (not recruiting), Estimated PCD: 2022-12-27
Product
RifaximinClinical trial
A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer PatientsStatus: Active (not recruiting), Estimated PCD: 2025-02-28
Drug
CisplatinClinical trial
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III StudyStatus: Recruiting, Estimated PCD: 2033-03-31
Drug
AN0025Drug
cyclophosphamideDrug
DocetaxelClinical trial
A Phase I, Single Arm, Prospective Study to Evaluate the Treatment of Genitourinary Syndrome of Menopause With Platelet Rich Plasma (PRP) in Women With a History of Breast CancerStatus: Completed, Estimated PCD: 2024-01-10
Drug
R-CHOPDrug
TiragolumabProduct
PembrolizumabClinical trial
Safely Stopping Pre-Medications in Patients Receiving Paclitaxel: A Randomized TrialStatus: Recruiting, Estimated PCD: 2024-12-31
Product
CimetidineClinical trial
Phase I Clinical Trial Assessing the Combination of Chemokine Modulation With Neoadjuvant Chemotherapy in Triple Negative Breast CancerStatus: Completed, Estimated PCD: 2022-05-24
Drug
CelecoxibProduct
CyclophosphamideClinical trial
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Triple Negative Breast Cancer (TNBC)Status: Not yet recruiting, Estimated PCD: 2026-12-31
Product
IpilimumabProduct
Vaccine TherapyClinical trial
A Phase-2, Two-Cohort Trial of Neoadjuvant Nab-Paclitaxel and Alpelisib in Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN AlterationsStatus: Active (not recruiting), Estimated PCD: 2025-12-31
Drug
AlpelisibDrug
AbraxaneProduct
DoxorubicinProduct
PaclitaxelDrug
RintatolimodClinical trial
A Phase 1B Trial Evaluating the Safety of Ribociclib, Tucatinib, and Trastuzumab in Patients With Metastatic, HER2+ Breast Cancer and a Multicenter, Randomized, Open-Label, Phase 2 Study of Preoperative Treatment With Ribociclib,Ttrastuzumab, Tucatinib, and Fulvestrant Versus Docetaxel, Carboplatin,Ttrastuzumab, and Pertuzumab in HR+/HER2+ Breast Cancer and Ribociclib, Trastuzumab, and Tucatinib Versus Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab in Patients With HR-/HER2+ Breast CancerStatus: Recruiting, Estimated PCD: 2025-04-01
Product
CarboplatinProduct
FulvestrantProduct
PertuzumabProduct
RibociclibDrug
TrastuzumabDrug
TucatinibProduct
DexamethasoneProduct
DiphenhydramineClinical trial
Phase I/II Safety and Efficacy Study of Autophagy Inhibition With Hydroxychloroquine to Augment the Antiproliferative and Biological Effects of Pre-Operative Palbociclib Plus Letrozole for Estrogen Receptor-Positive and HER2-Negative Breast CancerStatus: Completed, Estimated PCD: 2024-04-17
Product
HydroxychloroquineProduct
LetrozoleProduct
PalbociclibProduct
FamotidineProduct
RanitidineClinical trial
A Randomized Window of Opportunity Study of Preoperative Letrozole and Simvastatin Versus Letrozole Alone in Stage I-III Hormone Receptor Positive, HER2 Negative Breast CancerStatus: Recruiting, Estimated PCD: 2025-04-15
Product
SimvastatinClinical trial
Window Trial of Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer (a BEAUTY Study*)Status: Recruiting, Estimated PCD: 2024-07-31
Product
AbemaciclibClinical trial
A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab [MEDI4736]) Plus Anti-CTLA-4 Antibody (Tremelimumab) in Patients With Hormone Receptor Positive, HER2 Negative Breast CancerStatus: Completed, Estimated PCD: 2019-01-31
Product
TremelimumabClinical trial
Time Restricted Eating And Metformin (TEAM) in Invasive Breast Cancer (IBC) or Ductal Carcinoma in Situ (DCIS). A Randomized, Phase IIb, Window of Opportunity Presurgical Trial.Status: Recruiting, Estimated PCD: 2025-11-20
Product
Extended Release MetforminClinical trial
A Phase II Single Arm Trial Evaluating the Safety and Efficacy of Anhydrous Enol-Oxaloacetate on Improving Cognitive Complaints in Breast Cancer SurvivorsStatus: Recruiting, Estimated PCD: 2024-11-01
Product
Anhydrous Enol-oxaloacetateClinical trial
Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American WomenStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Pharmacodynamic Study of Estrogen Suppression Threshold-Directed Therapy (ESTDT) of Anastrozole as Adjuvant Therapy for Early Stage Breast CancerStatus: Completed, Estimated PCD: 2022-12-12
Product
AnastrozoleClinical trial
A Pilot Trial of Preoperative Oral Microbiota-Based Investigational New Drug, RBX7455 to Target Immune Response in Patients With Operable Stage I-III Breast CancerStatus: Terminated, Estimated PCD: 2023-01-11
Product
RBX7455Clinical trial
Association of HSD3B1 Genotype With Response to Preoperative Letrozole Therapy Among Postmenopausal Women With Estrogen-Receptor Positive (ER+) HER2/Neu-Negative (HER2-) Invasive Carcinomas of the BreastStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase II Study of Concurrent WOKVAC Vaccination With Neoadjuvant Chemotherapy and HER2-Targeted Monoclonal Antibody TherapyStatus: Recruiting, Estimated PCD: 2024-10-30
Product
pUMVC3-IGFBP2-HER2-IGF1RClinical trial
A Phase 1 Study of Ipilumumab, Nivolumab and Talimogene Laherparepvec Preoperative Treatment of Localized Breast Cancer-deletedStatus: Terminated, Estimated PCD: 2023-05-17
Drug
LurbinectedinDrug
T-VECClinical trial
A Phase II Trial of The Immunogenicity of a DNA Plasmid Based Vaccine (STEMVAC) Encoding Th1 Selective Epitopes From Five Antigens Associated With Breast Cancer Stem Cells (MDM2, YB1, SOX2, CDC25B, CD105) in Participants With Early Stage Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2025-04-30
Drug
GM-CSFProduct
Talimogene LaherparepvecClinical trial
Engineering Gut Microbiome to Target Cancer-Immune Microenvironment in Breast and Lung CancerStatus: Completed, Estimated PCD: 2023-03-08
Product
ProbioticClinical trial
Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast CancerStatus: Recruiting, Estimated PCD: 2026-05-31
Clinical trial
A Phase Ib/II Study of the Safety and Pharmacology of Nilotinib to Prevent Paclitaxel-Induced Peripheral Neuropathy in Patients With Breast CancerStatus: Recruiting, Estimated PCD: 2024-01-02
Product
NilotinibDrug
doxorubicinClinical trial
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor TherapyStatus: Recruiting, Estimated PCD: 2033-05-31
Drug
mFOLFOX6Clinical trial
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and TucatinibStatus: Recruiting, Estimated PCD: 2028-01-01
Product
Trastuzumab EmtansineProduct
PlaceboClinical trial
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete ResponseStatus: Recruiting, Estimated PCD: 2026-10-31
Clinical trial
Interim FDG-PET/CT for PreDIcting REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT TrialStatus: Recruiting, Estimated PCD: 2025-03-31